Terra Alpha Investments LLC Reduces Stock Holdings in IQVIA Holdings Inc. $IQV

Terra Alpha Investments LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 26.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,791 shares of the medical research company’s stock after selling 3,102 shares during the period. IQVIA accounts for about 2.0% of Terra Alpha Investments LLC’s holdings, making the stock its 19th biggest position. Terra Alpha Investments LLC’s holdings in IQVIA were worth $1,982,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of IQV. Claret Asset Management Corp raised its position in IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after purchasing an additional 49 shares during the last quarter. Versant Capital Management Inc boosted its stake in IQVIA by 6.3% during the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after purchasing an additional 53 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. boosted its stake in IQVIA by 3.3% during the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after purchasing an additional 58 shares during the period. Brookstone Capital Management boosted its stake in IQVIA by 2.2% during the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after purchasing an additional 63 shares during the period. Finally, Private Advisor Group LLC boosted its stake in IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after purchasing an additional 63 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE:IQV opened at $169.56 on Friday. The firm’s fifty day moving average price is $170.14 and its 200 day moving average price is $199.19. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market cap of $28.30 billion, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 1.63 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the firm posted $2.70 EPS. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has approved a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IQV. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Evercore reiterated an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Mizuho set a $215.00 price target on shares of IQVIA in a research note on Monday, February 23rd. Royal Bank Of Canada began coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Finally, Stifel Nicolaus decreased their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $225.69.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.